New Endowed Professorship of Pharmaceutical Technology

Signed the agreement on the new endowed ship: Rector Bernhard Eitel (second from

Signed the agreement on the new endowed ship: Rector Bernhard Eitel (second from the left) and Frank Schubert, Managing Director of Lipoid GmbH (second from the right), with Peter Hölig, Head of Business Development (right), and Christian Klein, Director of IPMB (left). | © Rothe

In order to promote research and teaching in the field of Pharmaceutical Technology, Lipoid GmbH (Ludwigshafen) is endowing a new junior professorship. It will be located at the Institute of Pharmacy and Molecular Biotechnology (IPMB) at Heidelberg University and funded with a total amount of 1.2 million euros. An agreement to this effect has just been signed by Bernhard Eitel, Rector of Ruperto Carola, and Christian Klein, Managing Director of IPMB, with - for the company - Dr Frank Schubert, Managing Director of Lipoid GmbH, and Dr Peter Hölig, Head of Business Development. The endowed professorship is planned for six years and focuses on the area of phospholipids.

"The newly created professorship will expand the range of Heidelberg Life Sciences by an important field of teaching and research," underlined the Rector when the contract was signed on 15 June 2021. Phospholipids are complex lipids, which are the main component of all cell membranes and to be found in every living cell. An important area of research of the new professorship will be pharmaceutical applications and pharmaceuticals containing phospholipids. Lipoid has decades of experience and is a leading supplier of pharmaceutical phospholipids on an industrial scale. These natural and nature-identical phospholipids are based, for example, on soya, sunflowers and yoke of egg. Heidelberg University and the Lipoid company will try to continue the funding beyond the six years that have just been agreed.


This site uses cookies and analysis tools to improve the usability of the site. More information. |